参考文献/References:
[1] LI G,ZHANG L, HAN N, et al.Increased Th17 and Th22 cell percentages predict acute lung injury in patients with sepsis[J].Lung,2020,198(4): 687-693.
[2] XIE J,WANG H,KANG Y,et al.The epidemiology of sepsis in chinese ICUs[J].Crit Care Med,2020,48(3):209-218.
[3] 丁宣尹, 雷迁.脓毒症心肌病发病机制研究进展[J].实用医院临床杂志,2023,20(6):182-185.
[4] 卓荦,史家欣.PI3K/AKT/mTOR信号通路对脓毒症中细胞自噬的调控研究进展[J].重庆医学,2019,48(11):1927-1929.
[5] 王会迟,田璐,郑毅,等.脓毒症合并心肌功能障碍患者心肌损伤,血流动力学变化与心脏结构和功能的关系[J].疑难病杂志, 2023, 22(1):25-29.
[6] 王凤新,张博,白秀萍.脓毒症心肌损伤机制研究进展[J].内科急危重症杂志,2018,24(5):437-440.
[7] FATTAHI F, KALBITZ M, MALAN E A, et al.Comple-ment-induced activation of MAPKs and Akt during sepsis: role in cardiac dysfunction [J].FASEB J, 2017, 31(9): 4129-4139.
[8] JOHN S, JANE D, ALICE B.The molecular mechanisms of sepsis-induced cardiomyopathy [J].Nature Medicine, 2022, 28(5): 1000-1010.
[9] WILLIAM J, EMILY D, CHEN M, et al.Protective effects of BPV on cardiac function in a rat model of sepsis [J].Journal of the American Heart Association, 2023, 12(3): e022345.
[10] LI H, WANG X M, ZHANG L.Cellular and molecular basis of myocardial dysfunction in sepsis[J].Circulation Research, 2021, 128(7): 935-950.
[11] WANG M, ZHAO Y F, SUN L.Novel therapeutic strategies for treating sepsis-associated myocardial injury[J].Critical Care Medicine, 2022, 50(2):220-230.
相似文献/References:
[1]林兴盛,石松长.肝素治疗对严重脓毒症患者肺、肾功能的影响[J].福建医药杂志,2017,39(4):108.
[2]林爱芳,甘巧蓉,吴旭玮.血清程序性死亡蛋白1和高迁移率族蛋白1水平与脓毒症并发肝损伤的相关性研究[J].福建医药杂志,2024,46(01):8.[doi:10.20148/j.fmj.2024.01.003]
LIN Aifang,GAN Qiaorong,WU Xuwei.Study on correlation of serum PD1 and HMGB1 with liver injury in patients with sepsis[J].FUJIAN MEDICAL JOURNAL,2024,46(07):8.[doi:10.20148/j.fmj.2024.01.003]
[3]林康昵.肿瘤重症监护室脓毒症患者预后影响因素分析[J].福建医药杂志,2024,46(05):14.[doi:10.20148/j.fmj.2024.05.004]
LIN Kangni.Risk factors for sepsis patients with malignant tumor in intensive care unit[J].FUJIAN MEDICAL JOURNAL,2024,46(07):14.[doi:10.20148/j.fmj.2024.05.004]